145 related articles for article (PubMed ID: 35489446)
1. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity.
Shen L; Xiao Y; Zhang C; Li S; Teng X; Cui L; Liu T; Wu N; Lu Z
Cancer Lett; 2022 Jul; 538():215710. PubMed ID: 35489446
[TBL] [Abstract][Full Text] [Related]
2. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
Front Immunol; 2020; 11():482. PubMed ID: 32528460
[TBL] [Abstract][Full Text] [Related]
3. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
5. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.
Alizadeh D; Wong RA; Yang X; Wang D; Pecoraro JR; Kuo CF; Aguilar B; Qi Y; Ann DK; Starr R; Urak R; Wang X; Forman SJ; Brown CE
Cancer Immunol Res; 2019 May; 7(5):759-772. PubMed ID: 30890531
[TBL] [Abstract][Full Text] [Related]
6. Reducing
Ghassemi S; Nunez-Cruz S; O'Connor RS; Fraietta JA; Patel PR; Scholler J; Barrett DM; Lundh SM; Davis MM; Bedoya F; Zhang C; Leferovich J; Lacey SF; Levine BL; Grupp SA; June CH; Melenhorst JJ; Milone MC
Cancer Immunol Res; 2018 Sep; 6(9):1100-1109. PubMed ID: 30030295
[TBL] [Abstract][Full Text] [Related]
7. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.
Yang S; Gattinoni L; Liu F; Ji Y; Yu Z; Restifo NP; Rosenberg SA; Morgan RA
Cancer Immunol Immunother; 2011 May; 60(5):739-49. PubMed ID: 21305379
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
9. Differential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells.
Madden MZ; Ye X; Chi C; Fisher EL; Wolf MM; Needle GA; Bader JE; Patterson AR; Reinfeld BI; Landis MD; Hathaway ES; Muka JE; O'Neil RT; Karijolich J; Philip M; Rathmell JC
J Immunol; 2023 Aug; 211(4):563-575. PubMed ID: 37341499
[TBL] [Abstract][Full Text] [Related]
10. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
11. The potential role of short chain fatty acids improving
González-Brito A; Uribe-Herranz M
Front Immunol; 2023; 14():1083303. PubMed ID: 36742300
[TBL] [Abstract][Full Text] [Related]
12.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
13. Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells.
Zhao S; Wang C; Lu P; Lou Y; Liu H; Wang T; Yang S; Bao Z; Han L; Liang X; Ma C; Gao L
J Immunother Cancer; 2021 Nov; 9(12):. PubMed ID: 34853180
[TBL] [Abstract][Full Text] [Related]
14. Role of CAR T Cell Metabolism for Therapeutic Efficacy.
Rial Saborido J; Völkl S; Aigner M; Mackensen A; Mougiakakos D
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358860
[TBL] [Abstract][Full Text] [Related]
15. Promoting thiol expression increases the durability of antitumor T-cell functions.
Kesarwani P; Al-Khami AA; Scurti G; Thyagarajan K; Kaur N; Husain S; Fang Q; Naga OS; Simms P; Beeson G; Voelkel-Johnson C; Garrett-Mayer E; Beeson CC; Nishimura MI; Mehrotra S
Cancer Res; 2014 Nov; 74(21):6036-6047. PubMed ID: 25164014
[TBL] [Abstract][Full Text] [Related]
16. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.
Petersen CT; Hassan M; Morris AB; Jeffery J; Lee K; Jagirdar N; Staton AD; Raikar SS; Spencer HT; Sulchek T; Flowers CR; Waller EK
Blood Adv; 2018 Feb; 2(3):210-223. PubMed ID: 29386194
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
18. CAR-T Cell Performance: How to Improve Their Persistence?
López-Cantillo G; Urueña C; Camacho BA; Ramírez-Segura C
Front Immunol; 2022; 13():878209. PubMed ID: 35572525
[TBL] [Abstract][Full Text] [Related]
19. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
Xu Y; Zhang M; Ramos CA; Durett A; Liu E; Dakhova O; Liu H; Creighton CJ; Gee AP; Heslop HE; Rooney CM; Savoldo B; Dotti G
Blood; 2014 Jun; 123(24):3750-9. PubMed ID: 24782509
[TBL] [Abstract][Full Text] [Related]
20. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
